Biophan Announces Online Availability of New Video on Potentially Life-Saving `MYO-VAD' Ventricular Assist Device; Video is First in a Three-Part Series Discussing Biophan's Strategic Initiative to Address $28 Billion Cardiac Assist Device Opportunity.

ROCHESTER, N.Y. -- Biophan Technologies, Inc. (OTCBB: BIPH), a developer of next-generation biomedical technology, announced today the online availability of a new streaming video presentation about its entry into the fast-growing market for cardiac assist devices used to keep patients alive throughout episodes of heart failure and heart disease.

Biophan recently announced a Letter of Intent with MYOTECH, LLC to acquire marketing rights to MYOTECH's breakthrough Ventricular Assist Device (VAD). Under the agreement, Biophan will also oversee the development and regulatory approval of MYOTECH's MYO-VAD(TM) cardiac assist technology, as well as all future MYOTECH development programs. In addition, at closing Biophan will acquire a substantial minority interest with the right to acquire a controlling interest in MYOTECH.

The MYO-VAD device can potentially assist in the medical treatment of countless patients in a worldwide market for cardiac devices that is projected to reach $28 billion, making it one of the fastest growing segments of the biomedical marketplace. The new video about MYO-VAD features Biophan CEO, Michael Weiner, and Jeff Helfer, Biophan Vice President of Engineering and President of Biophan's Cardiovascular Division. It is the first in a three-part series of videos about the MYO-VAD.

"Recent medical studies have shown that ventricular assist devices are superior to medical management that center on drug therapies," Mr. Weiner notes in the video. "But unfortunately, current VADs are associated with serious complications, including high rates of often fatal clotting, stroke, bleeding, and infection. While the therapeutic benefits of VADs are exciting, the complications associated with the devices available for use today are still completely unacceptable."

Some leading medical device companies have already expressed initial interest in the MYO-VAD device. It is designed to assist the best blood pump known to man - the heart - to maintain healthy blood flow during heart failure. Moreover, the device is less invasive and therefore could be safer, simpler and more affordable than other devices on the market. Previous versions of Direct Mechanical Ventricular Actuation (DMVA) technology have been implanted experimentally in 700 animals, and successfully in five patients - helping to save their lives, thus demonstrating the effectiveness of the DMVA technology upon which the MYO-VAD design is based.

To view the video online, please visit http://www.tril01.com/biophan/myovad.html.

About MYOTECH, LLC

MYOTECH, LLC, is a privately-held medical technology development company, formed in 2003 to commercialize a family of medical products based upon Direct Mechanical Ventricular Actuation ("DMVA") cardiac assist technology. This technology has permitted the development of minimally invasive heart assist devices that promise to provide more effective treatment for patients with many types of heart failure. MYOTECH has relationships with leading physicians and medical institutions. They have assisted MYOTECH in both research and planning. MYOTECH has several pending patents pertaining to the DMVA technology.

About Biophan Technologies

Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and image compatible with the magnetic resonance imaging (MRI) environment. The Company develops technologies that enable implanted medical systems such as pacemakers, interventional surgical devices such as catheters and guidewires, and devices such as stents to be safely and effectively imaged under MRI. Biophan is developing these same technologies to provide new MRI contrast agents. Other applications include drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 144 U.S. patents, licenses, or applications. This total includes 41 issued U.S. patents, 9 recently-allowed applications that will issue as patents in the near future, and 94 pending applications at various stages of examination at the U.S. Patent and Trademark Office, plus international applications. The patents cover areas including nanotechnology (nanomagnetic particle coatings), medical device designs, radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development and licensing agreements with Boston Scientific (NYSE: BSX - News) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects, or believes may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology, the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.